Benefit Ledger · provisional · Other

STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial

A pill from AstraZeneca failed to improve outcomes in closely watched breast cancer study, a result that could limit the use of the medicine.

12 Sep 2026Tier 1 UsefulMethodology 0.1

Current score

+0.00

1 base · Useful (tier 1 of 5, 1 pts)

× 0.1000 attribution · Minor documented assistance

× 0.1000 evidence · Firsthand or social claim

× 0.2000 realization · Proposed

× 0.5000 durability

Event-level product before credit split: 0.00

Auto-published from news ingest as a provisional placeholder. Score is conservative until a named release is identified and the record is rescored.

What happened

A pill from AstraZeneca failed to improve outcomes in closely watched breast cancer study, a result that could limit the use of the medicine.

Version unspecified

+0.00

Unspecified system mentioned or implied by a news item. Remap to a named release when identified.

News ingest does not infer a named model from the publisher alone. Attribution stays unspecified until a release is identified.

Attribution 0.1000 · Credit share 100% · Unknown

STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial
outcome · supported

primary sources